MDT

86.08

+0.56%↑

121.65

+2.99%↑

VEEV

167.9

+0.35%↑

HQY

85.93

+1.81%↑

NEOG

9.5

+2.81%↑

MDT

86.08

+0.56%↑

121.65

+2.99%↑

VEEV

167.9

+0.35%↑

HQY

85.93

+1.81%↑

NEOG

9.5

+2.81%↑

MDT

86.08

+0.56%↑

121.65

+2.99%↑

VEEV

167.9

+0.35%↑

HQY

85.93

+1.81%↑

NEOG

9.5

+2.81%↑

MDT

86.08

+0.56%↑

121.65

+2.99%↑

VEEV

167.9

+0.35%↑

HQY

85.93

+1.81%↑

NEOG

9.5

+2.81%↑

MDT

86.08

+0.56%↑

121.65

+2.99%↑

VEEV

167.9

+0.35%↑

HQY

85.93

+1.81%↑

NEOG

9.5

+2.81%↑

Home・Aandelen Lijst・Mirati Therapeutics Inc

Mirati Therapeutics Inc

Gesloten

SectorGezondheidszorg

Buy Sell

Overzicht

Wijziging aandelenprijs

24u

Huidig

Min

Max

Aanbevelingen
By TipRanks
Aanbevelingen	Neutraal
12 Maanden Prognose	-0.05% downside

Nieuwssentiment

By Acuity

43%

57%

115 / 348 Rangschikking in Healthcare

Mirati Therapeutics Inc Grafiek

Eerdere prestaties zijn geen betrouwbare indicator voor toekomstige resultaten.

Gerelateerd nieuws

19 apr 2026, 23:48 UTC

Belangrijke Nieuwsgebeurtenissen

Crude Oil, Refined Product Prices Moving Higher Amid Renewed Tensions in Strait of Hormuz -- OPIS

19 apr 2026, 23:36 UTC

Belangrijke Nieuwsgebeurtenissen

NAB Raises Provisions as Australian Banks Face Iran Risks -- Update

19 apr 2026, 22:47 UTC

Belangrijke Nieuwsgebeurtenissen

National Australia Bank Adds $215 Million in Iran-Driven Credit Provisions

19 apr 2026, 21:14 UTC

Belangrijke Nieuwsgebeurtenissen

Week Ahead for FX, Bonds: U.S. Retail Sales, PMI Data Due as Focus Remains on Middle East

19 apr 2026, 21:14 UTC

Belangrijke Nieuwsgebeurtenissen

Week Ahead for FX, Bonds: U.S. Retail Sales, PMI -2-

19 apr 2026, 23:49 UTC

Marktinformatie

Belangrijke Nieuwsgebeurtenissen

Gold, Silver Decline Amid Renewed Inflation Concerns -- Market Talk

19 apr 2026, 23:46 UTC

Marktinformatie

Nikkei May Rise on Hopes for U.S.-Iran Peace Talks -- Market Talk

19 apr 2026, 23:38 UTC

Belangrijke Nieuwsgebeurtenissen

U.A.E. Asks U.S. About a Wartime Financial Lifeline -- Update

19 apr 2026, 23:36 UTC

Marktinformatie

Belangrijke Nieuwsgebeurtenissen

Oil Climbs on Renewed Tensions Over Strait of Hormuz -- Market Talk

19 apr 2026, 23:12 UTC

Belangrijke Nieuwsgebeurtenissen

Spot Gold Falls 1.2%, Spot Silver Drops 1.6% on Renewed Middle East Tensions

19 apr 2026, 23:10 UTC

Belangrijke Nieuwsgebeurtenissen

Front-Month Brent Crude Oil Futures Rise 5.8% to $95.64 per Barrel

19 apr 2026, 23:09 UTC

Belangrijke Nieuwsgebeurtenissen

Front-Month WTI Crude Oil Futures Climb 7.2% to $89.86 per Barrel

19 apr 2026, 23:08 UTC

Belangrijke Nieuwsgebeurtenissen

Front-Month Crude Oil Futures Climb on Renewed Tensions Over Strait of Hormuz

19 apr 2026, 21:20 UTC

Acquisities, Fusies, Overnames

Eli Lilly Nears Deal for Cancer Biotech -- WSJ

19 apr 2026, 21:20 UTC

Acquisities, Fusies, Overnames

Announcement Could Come As Soon As Monday, Sources Say -- WSJ

19 apr 2026, 21:20 UTC

Acquisities, Fusies, Overnames

Deal Expected to Be Worth Over $2B Plus Additional Milestones, Sources Say -- WSJ

19 apr 2026, 21:20 UTC

Acquisities, Fusies, Overnames

Eli Lilly Nears Deal for Kelonia Therapeutics, Sources Say -- WSJ

19 apr 2026, 20:03 UTC

Belangrijke Nieuwsgebeurtenissen

U.A.E. Central Bank Governor Khaled Mohamed Balama Raised Swap Idea With Treasury Secretary Scott Bessent in Washington -- WSJ

19 apr 2026, 20:03 UTC

Belangrijke Nieuwsgebeurtenissen

Emiratis Portrayed Swap Proposal as Precautionary and Preliminary in Case Iran War Drags On -- WSJ

19 apr 2026, 20:03 UTC

Belangrijke Nieuwsgebeurtenissen

The U.A.E. Has Opened Talks with U.S. for Currency Swap -- WSJ

19 apr 2026, 20:03 UTC

Belangrijke Nieuwsgebeurtenissen

U.A.E. Asks U.S. for a Wartime Financial Lifeline -- WSJ

18 apr 2026, 01:00 UTC

Belangrijke Nieuwsgebeurtenissen

As Economic Pressures Mount, Will Iran or the U.S. Blink First? -- WSJ

17 apr 2026, 22:58 UTC

Winsten

Grupo Aeroportuario Del Pacifico: Announces Filing of 2025 Annual Report and Form 20-F

17 apr 2026, 21:32 UTC

Marktinformatie

Cerebras IPO Adds to Big Year For AI Firms Going Public -- Market Talk

17 apr 2026, 21:22 UTC

Marktinformatie

Global Forex and Fixed Income Roundup: Market Talk

17 apr 2026, 21:22 UTC

Marktinformatie

Moody's Downgrades Belgium to A1 -- Market Talk

17 apr 2026, 20:52 UTC

Winsten

Schwab Investors Get Spooked by JPMorgan's AI Strategy. The Big Worry Is Cash Sweeps. -- Barrons.com

17 apr 2026, 20:50 UTC

Marktinformatie

Winsten

Acquisities, Fusies, Overnames

Tech, Media & Telecom Roundup: Market Talk

17 apr 2026, 20:50 UTC

Marktinformatie

Basic Materials Roundup: Market Talk

17 apr 2026, 20:29 UTC

Winsten

These Stocks Are Today's Movers: Royal Caribbean, Dow Inc., Netflix, Intel, Albemarle, Autoliv, Alcoa, and More -- Barrons.com

Peer Vergelijking

Prijswijziging

Mirati Therapeutics Inc Prognose

Koersdoel

By TipRanks

-0.05% neerwaarts potentieel

12 Maanden Prognose

Gemiddelde 58.67 USD -0.05%

Hoogste 59 USD

Laagste 58 USD

Gebaseerd op 5 Wall Street-analisten die 12-maands prijsdoelen bieden voor Mirati Therapeutics Inc - Dist. in de afgelopen 3 maanden.

Beoordelingsconsensus

By TipRanks

Neutraal

5 ratings

Buy

Hold

Sell

Gebaseerd op 5 analisten die aandelenratings hebben gegeven aan Mirati Therapeutics Inc - Dist in de afgelopen 3 maanden.

Sentiment

By Acuity

115 / 348 Rangschikking in Gezondheidszorg

Financieel

Verkoop- en administratiekosten

Bedrijfskosten

Winst voor belastingen

Verkoop

Kosten van verkopen

Brutowinst op verkopen

EBITDA

Operationele winst

Over Mirati Therapeutics Inc

Mirati Therapeutics, Inc. is a clinical-stage oncology company. It is focused on developing therapeutics to address the genetic and immunological promoters of cancer. Its clinical programs consist of product candidates, including Adagrasib (MRTX849), MRTX1133, and Sitravatinib. MRTX849 is an oral small-molecule therapy designed to shrink difficult-to-treat cancers harboring the KRAS G12C mutation. MRTX1133 is a small molecule-inhibitor of the KRASG12D mutation, designed to treat patients with unmet need. Sitravatinib is a spectrum-selective receptor tyrosine kinase (RTK) inhibitor that can stimulate the body’s immune response to fight cancer. MRTX849 is in Phase III and Phase I/II clinical trials and MRTX1133 is in preclinical development. Sitravatinib is in a Phase III clinical trial, and Phase I/II clinical trials. It also has additional preclinical discovery programs, which includes first-in-class and best-in-class product candidates designed to address mutations and tumors.